Congress trades and big insider sales, sent the day they're filed. Free.
Open in Telegram

Spouse · ALNYLAM PHARMACEUTICALS, INC. · Alnylam Pharmaceuticals, Inc. - Common Stock
This transaction has not been scored yet.
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|
| 36 | Garg PushkalEVP Chief R&D | Open-market sale | SELL | $44K 123 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 20 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Open-market sale · 10b5-1 plan | SELL | $31K 85 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 19 | Garg PushkalEVP Chief R&D | Grant or award | A | — 3,800 sh | Jan 14, 2026 traded Jan 11, 2026 | |
| 29 | Greenstreet YvonneDirector, Chief Executive Officer | Open-market sale | SELL | $7,822 21 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 36 | Poulton Jeffrey V.EVP, Chief Financial Officer | Open-market sale | SELL | $28K 76 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 35 | Greenstreet YvonneDirector, Chief Executive Officer | Open-market sale | SELL | $279K 778 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 36 | Poulton Jeffrey V.EVP, Chief Financial Officer | Open-market sale | SELL | $32K 87 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 32 | Greenstreet YvonneDirector, Chief Executive Officer | Open-market sale | SELL | $96K 269 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 36 | Tanguler TolgaEVP, Chief Commercial Officer | Open-market sale | SELL | $34K 96 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 39 | Tanguler TolgaEVP, Chief Commercial Officer | Open-market sale | SELL | $56K 155 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 39 | Tanguler TolgaEVP, Chief Commercial Officer | Open-market sale | SELL | $73K 199 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 39 | Tanguler TolgaEVP, Chief Commercial Officer | Open-market sale | SELL | $80K 220 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 36 | Garg PushkalEVP Chief R&D | Open-market sale | SELL | $5,667 15 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 36 | Tanguler TolgaEVP, Chief Commercial Officer | Open-market sale | SELL | $745 2 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 32 | Greenstreet YvonneDirector, Chief Executive Officer | Open-market sale | SELL | $96K 261 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 36 | Garg PushkalEVP Chief R&D | Open-market sale | SELL | $17K 47 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 32 | Greenstreet YvonneDirector, Chief Executive Officer | Open-market sale | SELL | $215K 584 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 36 | Tanguler TolgaEVP, Chief Commercial Officer | Open-market sale | SELL | $35K 98 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 36 | Garg PushkalEVP Chief R&D | Open-market sale | SELL | $35K 98 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 39 | Garg PushkalEVP Chief R&D | Open-market sale | SELL | $80K 220 sh | Jan 14, 2026 traded Jan 12, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Midpoint = (low + high) / 2. Used only to rank and sum ranges; the true value can be anywhere in the range.
= $8,001
Cory A. Booker reported a sale (full) of Alnylam Pharmaceuticals, Inc. - Common Stock (owner: spouse). Members report a value range, not an exact amount, and do not report share counts or prices. Dates are as entered by the filer. A trade report is not evidence of wrongdoing.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.
Recorded votes from the House Clerk and Voteview (Senate). Listed by date; a vote near a trade is not evidence the two are related.